NO20053046L - 4-okso-1(3-substituerte fenyl-1,4-dihydro-1,8-naftyridin-3-karboksamidfosfodiesterase-4-inhibitorer. - Google Patents
4-okso-1(3-substituerte fenyl-1,4-dihydro-1,8-naftyridin-3-karboksamidfosfodiesterase-4-inhibitorer.Info
- Publication number
- NO20053046L NO20053046L NO20053046A NO20053046A NO20053046L NO 20053046 L NO20053046 L NO 20053046L NO 20053046 A NO20053046 A NO 20053046A NO 20053046 A NO20053046 A NO 20053046A NO 20053046 L NO20053046 L NO 20053046L
- Authority
- NO
- Norway
- Prior art keywords
- inhibitors
- naphthyridine
- dihydro
- oxo
- substituted phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Forbindelser representert ved formel (I) (D eller et farmasøytisk akseptabelt salt derav, er fosfodiesterase-4-inhibi- torer anvendbare ved behandling av astma og inflammasjon og anvendbare for å øke kognisjon.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42861102P | 2002-11-22 | 2002-11-22 | |
PCT/CA2003/001800 WO2004048374A1 (en) | 2002-11-22 | 2003-11-19 | 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20053046D0 NO20053046D0 (no) | 2005-06-21 |
NO20053046L true NO20053046L (no) | 2005-07-27 |
Family
ID=32393431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20053046A NO20053046L (no) | 2002-11-22 | 2005-06-21 | 4-okso-1(3-substituerte fenyl-1,4-dihydro-1,8-naftyridin-3-karboksamidfosfodiesterase-4-inhibitorer. |
Country Status (23)
Country | Link |
---|---|
US (2) | US7342024B2 (no) |
EP (1) | EP1565464B1 (no) |
JP (1) | JP4499571B2 (no) |
KR (1) | KR20050085112A (no) |
CN (1) | CN100475813C (no) |
AT (1) | ATE402175T1 (no) |
AU (1) | AU2003283167B2 (no) |
BR (1) | BR0316458A (no) |
CA (1) | CA2506648C (no) |
CL (1) | CL2004001050A1 (no) |
DE (1) | DE60322417D1 (no) |
EC (1) | ECSP055809A (no) |
HR (1) | HRP20050451A2 (no) |
IS (1) | IS7839A (no) |
MA (1) | MA27566A1 (no) |
MX (1) | MXPA05005413A (no) |
NO (1) | NO20053046L (no) |
NZ (1) | NZ539812A (no) |
PL (1) | PL377237A1 (no) |
RU (1) | RU2312865C2 (no) |
UA (1) | UA82208C2 (no) |
WO (1) | WO2004048374A1 (no) |
ZA (1) | ZA200503586B (no) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
IS7839A (is) * | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar |
US20090105479A1 (en) * | 2005-10-27 | 2009-04-23 | Merck & Co., Inc. | 4-Oxo-1-3-Substituted Phenyl-1,4-Dihydro-1,8-Napthyridene-3-Carboxamide Phosphodiesterase-4 Inhibitor and a Method of Preparing Same |
AR057555A1 (es) * | 2005-10-27 | 2007-12-05 | Merck Frosst Canada Ltd | Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo |
ME01648B (me) | 2006-07-05 | 2014-09-20 | Nycomed Gmbh | Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4,kao što je roflumilast, roflumilast-n-oksid za liječenje inflamatornih plućnih oboljenja |
US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
EP2074123B1 (en) | 2006-10-16 | 2012-12-05 | Bionomics Limited | Novel anxiolytic compounds |
KR101568884B1 (ko) * | 2007-03-14 | 2015-11-12 | 랜박시 래보러터리스 리미티드 | 포스포디에스테라제 저해제로서 피라졸로 (3,4-b) 피리딘 유도체 |
KR20100014565A (ko) * | 2007-04-11 | 2010-02-10 | 알콘 리서치, 리미티드 | 알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 tnfa의 억제제 및 항히스타민의 용도 |
US8563566B2 (en) * | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
EP2297106B1 (en) | 2008-05-27 | 2014-07-16 | AstraZeneca AB | Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states |
CA2773483A1 (en) * | 2009-10-01 | 2011-04-07 | Alcon Research, Ltd. | Olopatadine compositions and uses thereof |
CN103269584B (zh) * | 2010-07-01 | 2017-05-03 | 阿泽凡药物公司 | 用于治疗创伤后应激障碍的方法 |
US9023848B2 (en) | 2011-03-02 | 2015-05-05 | Bionomics Limited | Small-molecules as therapeutics |
US9133188B2 (en) | 2011-05-12 | 2015-09-15 | Bionomics Limited | Methods for preparing naphthyridines |
US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
CA2874988C (en) * | 2012-06-15 | 2016-05-24 | Bio-Pharm Solutions Co., Ltd. | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same |
EP2970177A1 (en) | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Indole compounds that activate ampk |
CN106316824B (zh) * | 2016-08-18 | 2018-10-19 | 广州康瑞泰药业有限公司 | 一种合成2-氟环丙烷甲酸的新方法 |
BR112019012176A2 (pt) * | 2016-12-16 | 2019-11-05 | Cstone Pharmaceuticals | composto, sal farmaceuticamente aceitável do mesmo ou isômero do mesmo, uso dos mesmos e composição farmacêutica |
WO2020139830A2 (en) | 2018-12-28 | 2020-07-02 | Regeneron Pharmaceuticals, Inc. | Treatment of respiratory disorders with arachidonate15-lipoxygenase (alox15) inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2808070A1 (de) | 1978-02-24 | 1979-08-30 | Bayer Ag | Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten |
US5328908A (en) | 1988-10-24 | 1994-07-12 | Procter & Gamble Pharmaceuticals, Inc. | Antimicrobial quinolone thioureas |
US5321029A (en) * | 1988-11-14 | 1994-06-14 | Beecham-Wuelfing Gmbh & Co.K.G. | Xanthines |
HUT76980A (hu) | 1994-08-29 | 1998-01-28 | Yamanouchi Pharmaceutical Co. Ltd. | Új naftiridinszármazékok és ezeket a vegyületeket tartalmazó gyógyászati készítmények |
DE69631423T2 (de) | 1995-08-02 | 2004-12-02 | Darwin Discovery Ltd., Slough | Chinolone und deren therapeutische verwendung |
EP0958297A1 (en) * | 1997-08-06 | 1999-11-24 | Suntory Limited | 1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor |
JPH11106385A (ja) * | 1997-08-06 | 1999-04-20 | Suntory Ltd | Iv型ホスホジエステラーゼ阻害作用を有する1−アリール−1,8−ナフチリジン−4−オン誘導体 |
DE59904535D1 (de) * | 1998-05-05 | 2003-04-17 | Altana Pharma Ag | Neue Benzonaphtyridin-N-oxide |
US6794447B1 (en) * | 2000-07-28 | 2004-09-21 | Taylor Made Golf Co., Inc. | Golf balls incorporating nanocomposite materials |
JP4460221B2 (ja) * | 2001-05-24 | 2010-05-12 | メルク フロスト カナダ リミテツド | 1−ビアリール−1,8−ナフチリジン−4−オン系ホスホジエステラーゼ−4阻害薬 |
KR100824233B1 (ko) * | 2001-10-10 | 2008-04-24 | 씨제이제일제당 (주) | 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난3,4-디하이드로-1h-나프탈렌 유도체 |
IS7839A (is) * | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar |
-
2003
- 2003-05-09 IS IS7839A patent/IS7839A/is unknown
- 2003-11-19 JP JP2004554102A patent/JP4499571B2/ja not_active Expired - Fee Related
- 2003-11-19 US US10/534,582 patent/US7342024B2/en not_active Expired - Fee Related
- 2003-11-19 UA UAA200506089A patent/UA82208C2/uk unknown
- 2003-11-19 PL PL377237A patent/PL377237A1/pl not_active Application Discontinuation
- 2003-11-19 BR BR0316458-6A patent/BR0316458A/pt not_active IP Right Cessation
- 2003-11-19 EP EP03775029A patent/EP1565464B1/en not_active Expired - Lifetime
- 2003-11-19 CN CNB2003801089525A patent/CN100475813C/zh not_active Expired - Fee Related
- 2003-11-19 MX MXPA05005413A patent/MXPA05005413A/es active IP Right Grant
- 2003-11-19 AT AT03775029T patent/ATE402175T1/de not_active IP Right Cessation
- 2003-11-19 CA CA2506648A patent/CA2506648C/en not_active Expired - Fee Related
- 2003-11-19 NZ NZ539812A patent/NZ539812A/en not_active IP Right Cessation
- 2003-11-19 KR KR1020057009238A patent/KR20050085112A/ko not_active Application Discontinuation
- 2003-11-19 AU AU2003283167A patent/AU2003283167B2/en not_active Ceased
- 2003-11-19 RU RU2005119644/04A patent/RU2312865C2/ru not_active IP Right Cessation
- 2003-11-19 DE DE60322417T patent/DE60322417D1/de not_active Expired - Lifetime
- 2003-11-19 WO PCT/CA2003/001800 patent/WO2004048374A1/en active IP Right Grant
-
2004
- 2004-01-23 US US10/764,229 patent/US7238706B2/en not_active Expired - Fee Related
- 2004-05-14 CL CL200401050A patent/CL2004001050A1/es unknown
-
2005
- 2005-05-05 ZA ZA200503586A patent/ZA200503586B/en unknown
- 2005-05-20 EC EC2005005809A patent/ECSP055809A/es unknown
- 2005-05-20 HR HR20050451A patent/HRP20050451A2/hr not_active Application Discontinuation
- 2005-06-16 MA MA28338A patent/MA27566A1/fr unknown
- 2005-06-21 NO NO20053046A patent/NO20053046L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2004048374A1 (en) | 2004-06-10 |
ATE402175T1 (de) | 2008-08-15 |
RU2312865C2 (ru) | 2007-12-20 |
ZA200503586B (en) | 2006-07-26 |
CN100475813C (zh) | 2009-04-08 |
EP1565464A1 (en) | 2005-08-24 |
CA2506648A1 (en) | 2004-06-10 |
JP4499571B2 (ja) | 2010-07-07 |
PL377237A1 (pl) | 2006-01-23 |
CN1738819A (zh) | 2006-02-22 |
RU2005119644A (ru) | 2006-01-20 |
DE60322417D1 (en) | 2008-09-04 |
CL2004001050A1 (es) | 2005-03-28 |
AU2003283167B2 (en) | 2009-01-08 |
ECSP055809A (es) | 2005-08-11 |
US20050107402A1 (en) | 2005-05-19 |
MXPA05005413A (es) | 2005-08-03 |
HRP20050451A2 (en) | 2006-02-28 |
IS7839A (is) | 2004-05-23 |
US7238706B2 (en) | 2007-07-03 |
JP2006508989A (ja) | 2006-03-16 |
NZ539812A (en) | 2007-12-21 |
UA82208C2 (en) | 2008-03-25 |
US20060058316A1 (en) | 2006-03-16 |
KR20050085112A (ko) | 2005-08-29 |
EP1565464B1 (en) | 2008-07-23 |
CA2506648C (en) | 2011-01-25 |
US7342024B2 (en) | 2008-03-11 |
BR0316458A (pt) | 2005-10-11 |
NO20053046D0 (no) | 2005-06-21 |
AU2003283167A1 (en) | 2004-06-18 |
MA27566A1 (fr) | 2005-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20053046L (no) | 4-okso-1(3-substituerte fenyl-1,4-dihydro-1,8-naftyridin-3-karboksamidfosfodiesterase-4-inhibitorer. | |
JO2311B1 (en) | Alkyl inhibitors Ariel phosphodiesterase-4 | |
PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
AU2002246728A1 (en) | Carboline derivatives | |
WO2003013484A3 (en) | N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents | |
GEP20094638B (en) | Benzimidazolone carboxylic acid derivatives | |
NO20044501L (no) | [1,4] diazenino [6,7,1-IJ] kinolin-derivater som antipsykotis og antifedme-midler | |
UA84712C2 (en) | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors | |
NO20052182L (no) | Nye forbindelser | |
AU2002249890A1 (en) | Carboline derivatives | |
TW200519111A (en) | N3-substituted imidazopyridine C-KIT inhibitors | |
AU2002213421A1 (en) | Condensed pyridoindole derivatives | |
SE0101932D0 (sv) | Pharmaceutical combinations | |
DE60112306D1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
WO2002070469A3 (en) | Selective pde3b inhibitors and use of the same in therapy | |
RS20060280A (en) | Novel keto-oxadiazole derivatives as cathepsin inhibitors | |
TW200508199A (en) | Novel compound | |
AU2002213419A1 (en) | Condensed pyridoindole derivatives | |
AU2001263278A1 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
AU2003258630A1 (en) | Pyrimidine derivatives as selective cox-2 inhibitors | |
AU2001296699A1 (en) | Condensed pyrazindione derivatives as pde inhibitors | |
AU2001261707A1 (en) | Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives | |
GB0319037D0 (en) | 7-Azaindole Derivatives | |
CA2423357A1 (en) | Fused heterocyclic derivatives as phosphodiesterase inhibitors | |
IS8034A (is) | Imídasó[4,5-B]kínólínafleiður og notkun þeirra sem NO-myndunarhemla |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |